Publication:
Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: A randomized controlled trial

0
0

Issued Date

2017

Resource Type

Article

File Type

application/pdf

ISSN

14726874

DOI

10.1186/s12905-017-0446-3

Other identifier(s)

2-s2.0-85029887493

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

BMC Women's Health. Vol 17, No.1 (2017)

Suggested Citation

Waiyaput W., Pumipichet S., Weerakiet S., Rattanasiri S., Sophonsritsuk A. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: A randomized controlled trial. BMC Women's Health. Vol 17, No.1 (2017). doi:10.1186/s12905-017-0446-3 Retrieved from: https://hdl.handle.net/20.500.14740/4074

Title

Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: A randomized controlled trial

Author(s)

Waiyaput W.
 Pumipichet S.
 Weerakiet S.
 Rattanasiri S.
 Sophonsritsuk A.

Abstract

Background: Simvastatin is a promising new drug for the treatment of endometriosis. It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and monocyte chemoattractant protein-1 (MCP-1). This study investigated the effect of pre-operative oral simvastatin administration on MCP-1 gene expression and serum MCP-1 protein levels in patients with endometriosis. Methods: A prospective, randomized, controlled study was conducted at the Reproductive Endocrinology Unit of the Department of Obstetrics and Gynecology at the Faculty of Medicine Ramathibodi Hospital. Forty women (mean age: 18-45 years) scheduled for laparoscopic surgery who had been diagnosed with endometriosis were recruited and randomly assigned to either a treatment group (20 mg/d of orally administered simvastatin for 2 weeks before surgery) or an untreated control group. Serum was collected before and after treatment and protein levels of MCP-1 were determined. MCP-1 and CD68 transcript levels were also quantified using real-time PCR on endometriotic cyst tissues. Results: MCP-1 gene expression on endometriotic cyst was not significantly different between the simvastatin-treated and untreated groups (P = 0.99). CD68 expression was higher in the treatment group compared to the control group, but this was not statistically significant (P = 0.055). Serum MCP-1 levels following simvastatin treatment were higher than in samples obtained before treatment (297.89 ± 70.77 and 255.51 ± 63.79 pg/ml, respectively) (P = 0.01). Conclusions: Treatment with 20 mg/d of simvastatin for 2 weeks did not reduce the expression of either the chemokine MCP-1 gene or macrophage-specific genes. Cumulatively, this suggests that simvastatin is not ideal for treating endometriosis because a higher dose of simvastatin (40-100 mg/d) would be needed to achieve the target outcome, which would significantly increase the risk of myopathy in patients. Trial registration: Thai Clinical Trials Registry TCTR20130627003Registered: June 27, 2013. © 2017 The Author(s).

Subject(s)

CD68 antigen
 Messenger RNA
 Monocyte chemotactic protein 1
 Simvastatin
 CCL2 protein, human
 Hydroxymethylglutaryl coenzyme A reductase inhibitor
 Monocyte chemotactic protein 1
 Simvastatin
 Adult
 Article
 Clinical article
 Controlled study
 Endometriosis
 Female
 Gene expression
 Human
 Human tissue
 Laparoscopic surgery
 Randomized controlled trial
 Real time polymerase chain reaction
 Adolescent
 Antagonists and inhibitors
 Comparative study
 Drug effects
 Endometriosis
 Genetics
 Middle aged
 Prospective study
 Young adult
 Adolescent
 Adult
 Chemokine CCL2
 Endometriosis
 Female
 Gene Expression
 Humans
 Hydroxymethylglutaryl-CoA Reductase Inhibitors
 Middle Aged
 Prospective Studies
 Simvastatin
 Young Adult

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/4074

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By